FDA/CDC

FDA approves new type 2 diabetes drug bexagliflozin


 

The U.S. Food and Drug Administration has approved bexagliflozin (Brenzavvy, TheracosBio) for the treatment of adults with type 2 diabetes.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

The once-daily 20-mg oral sodium-glucose cotransporter 2 (SGLT2) inhibitor is indicated as an adjunct to diet and exercise to improve glycemic control for those with type 2 diabetes, but not type 1 diabetes. It can be used in adults with an estimated glomerular filtration rate (eGFR) > 30 mL/min per 1.73 m2.

Approval was based on results from 23 clinical trials with more than 5,000 participants, including more than 300 patients with stage 3 kidney disease (eGFR < 60 and > 30 mL/min per 1.73 m2).

In the phase 3 studies, bexagliflozin significantly reduced hemoglobin A1c and fasting blood glucose at 24 weeks as monotherapy or as add-on to metformin and other glucose-lowering drugs and combinations. It also produced modest reductions in body weight and systolic blood pressure.

In the phase 3 Bexagliflozin Efficacy and Safety Trial (BEST) cardiovascular outcomes trial, the drug met its efficacy and safety objectives in patients at high cardiovascular risk. Noninferiority was demonstrated for the composite outcome of cardiovascular death, myocardial infarction, stroke, or unstable angina.

“As a class of drugs, SGLT2 inhibitors have shown tremendous benefit in treating adults with type 2 diabetes,” said Mason Freeman, MD, director of the Translational Research Center at Massachusetts General Hospital, Boston, in a press release from TheracosBio.

“Being involved in all of the clinical trials for Brenzavvy, I am greatly impressed with the efficacy of the drug in reducing blood glucose levels and I believe it is an important addition to the SGLT2 inhibitor class of drugs.”

As with other SGLT2 inhibitors, adverse events seen in the trials include ketoacidosis, lower limb amputation, volume depletion, urosepsis, pyelonephritis, Fournier’s gangrene, genital mycotic infections, and hypoglycemia when used with insulin or insulin secretagogues.

Bexagliflozin joins an already crowded field of SGLT2 inhibitors, some of which have been approved for additional cardiovascular and kidney indications.

Of interest, bexagliflozin was approved by the FDA for diabetes in cats in December 2022, as the first oral new animal drug to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin.

A version of this article first appeared on Medscape.com.

Recommended Reading

Dubious diagnosis: Is there a better way to define ‘prediabetes’?
MDedge Internal Medicine
FDA approves Wegovy (semaglutide) for obesity in teens 12 and up
MDedge Internal Medicine
Diabetes surge expected in young people
MDedge Internal Medicine
Latest steps toward reducing U.S. insulin cost begin in 2023
MDedge Internal Medicine
PPI use in type 2 diabetes links with cardiovascular events
MDedge Internal Medicine
Fair access crucial for new diabetes/kidney disease drugs, say guidelines
MDedge Internal Medicine
Oramed oral insulin fails to meet goal in type 2 diabetes
MDedge Internal Medicine
Metformin monotherapy not always best start in type 2 diabetes
MDedge Internal Medicine
Diet packed with fast food found hard on the liver
MDedge Internal Medicine
Nitrite food additives may increase risk of type 2 diabetes
MDedge Internal Medicine